Advertisement

Current Heart Failure Reports

, Volume 16, Issue 5, pp 150–156 | Cite as

Updates on Heart Transplantation

  • Kevin S. Shah
  • Michelle M. Kittleson
  • Jon A. Kobashigawa
Updates in Advanced Heart Failure (E. Rame and M. St. John Sutton, Section Editors)
  • 359 Downloads
Part of the following topical collections:
  1. Topical Collection on Updates in Advanced Heart Failure

Abstract

Purpose of Review

The purpose of this review is to provide a comprehensive update on recent advances in heart transplantation.

Recent Findings

Heart transplantation is now an established therapy for end-stage heart failure, though challenges still exist. However, multiple advances over the past few years will improve the survival and quality of life of heart transplant recipients. These advances include acceptance of previously considered marginal donor hearts, revisions to the donor heart allocation policy, advances in desensitization regimens, tailoring of immunosuppression regimens, and improvement in the diagnosis of rejection and allograft vasculopathy.

Summary

Heart transplantation is evolving to provide better quality of life and survival to higher risk recipients with methods to broaden the donor pool, make the best use of existing organs, and refine the management of sensitization and diagnosis of rejection and allograft vasculopathy.

Keywords

Heart transplant Allocation Mechanical circulatory support Allograft rejection Surveillance Endomyocardial biopsy 

Notes

Compliance with Ethical Standards

Conflict of Interest

Kevin S. Shah and Michelle M. Kittleson declare no conflicts of interest. Jon A. Kobashigawa reports grants from Novartis, grants from Alexion, grants and personal fees from CareDx, grants from Sanofi, all outside the submitted work.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Stehlik J, Kobashigawa J, Hunt SA, Reichenspurner H, Kirklin JK. Honoring 50 years of clinical heart transplantation in circulation: in-depth state-of-the-art review. Circulation. 2018;137:71–87.CrossRefGoogle Scholar
  2. 2.
    • Lund LH, Khush KK, Cherikh WS, Goldfarb S, Kucheryavaya AY, Levvey BJ, et al. The registry of the International Society for Heart and Lung Transplantation: thirty-fourth adult heart transplantation report—2017; focus theme: allograft ischemic time. J Hear Lung Transplant. 2017;36:1037–46.  https://doi.org/10.1016/j.healun.2017.07.019. This statement provides updated data regarding heart transplant donor and recipient demographics, outcomes, with an emphasis on the effect of allograft ischemic time on outcomes. CrossRefGoogle Scholar
  3. 3.
    Colvin M, Smith JM, Hadley N, Skeans MA, Carrico R, Uccellini K, et al. OPTN/SRTR 2016 annual data report: heart. Am J Transplant. 2018;18:291–362.  https://doi.org/10.1111/ajt.14561.CrossRefPubMedGoogle Scholar
  4. 4.
    Albertoni G, Castelo Girão MJB, Schor N. Mini review: current molecular methods for the detection and quantification of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus type 1. Int J Infect Dis. 2014;25:145–9.CrossRefGoogle Scholar
  5. 5.
    Levitsky J, Formica RN, Bloom RD, Charlton M, Curry M, Friedewald J, Friedman J, Goldberg D, Hall S, Ison M, Kaiser T, Klassen D, Klintmalm G, Kobashigawa J, Liapakis A, O’Conner K, Reese P, Stewart D, Terrault N, Theodoropoulos N, Trotter J, Verna E, Volk M. The American Society of Transplantation consensus conference on the use of hepatitis C Viremic donors in solid organ transplantation. In: American Journal of Transplantation. 2017.Google Scholar
  6. 6.
    Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370:1879–88.  https://doi.org/10.1056/NEJMoa1402355.CrossRefPubMedGoogle Scholar
  7. 7.
    Morales JM, Campistol JM, Domínguez-Gil B, Andrés A, Esforzado N, Oppenheimer F, et al. Long-term experience with kidney transplantation from hepatitis C-positive donors into hepatitis c-positive recipients. Am J Transplant. 2010;10:2453–62.  https://doi.org/10.1111/j.1600-6143.2010.03280.x.CrossRefPubMedGoogle Scholar
  8. 8.
    Sawinski D, Kaur N, Ajeti A, Trofe-Clark J, Lim M, Bleicher M, et al. Successful treatment of hepatitis C in renal transplant recipients with direct-acting antiviral agents. Am J Transplant. 2016;16:1588–95.  https://doi.org/10.1111/ajt.13620.CrossRefPubMedGoogle Scholar
  9. 9.
    Schlendorf KH, Zalawadiya S, Shah AS, Wigger M, Chung CY, Smith S, et al. Early outcomes using hepatitis C–positive donors for cardiac transplantation in the era of effective direct-acting anti-viral therapies. J Hear Lung Transplant. 2018;37:763–9.  https://doi.org/10.1016/j.healun.2018.01.1293.CrossRefGoogle Scholar
  10. 10.
    Kobashigawa J, Khush K, Colvin M, Acker M, Van Bakel A, Eisen H, Naka Y, Patel J, Baran DA, Daun T, Luu M, Olymbios M, Rogers J, Jeevanandam V, Esmailian F, Pagani FD, Lima B, Stehlik J. Report from the American Society of Transplantation conference on donor heart selection in adult cardiac transplantation in the United States. In: American Journal of Transplantation. 2017.Google Scholar
  11. 11.
    Meyer DM, Rogers JG, Edwards LB, Callahan ER, Webber SA, Johnson MR, et al. The future direction of the adult heart allocation system in the United States. Am J Transplant. 2015;15:44–54.  https://doi.org/10.1111/ajt.13030.CrossRefPubMedGoogle Scholar
  12. 12.
    Kobashigawa JA, Johnson M, Rogers J, Vega JD, Colvin-Adams M, Edwards L, Meyer D, Luu M, Reinsmoen N, Dipchand AI, Feldman D, Kormos R, Mancini D, Webber S. Report from a forum on US heart allocation policy. In: American Journal of Transplantation. 2015.Google Scholar
  13. 13.
    • Davies RR, Farr M, Silvestry S, Callahan LR, Edwards L, Meyer DM, et al. The new United States heart allocation policy: progress through collaborative revision. J Heart Lung Transplant. This article provides a summary of the rationale behind and the details regarding the heart allocation policy change within the U.S. 2017;36:595–6.Google Scholar
  14. 14.
    Nwakanma LU, Williams JA, Weiss ES, Russell SD, Baumgartner WA, Conte JV. Influence of pretransplant panel-reactive antibody on outcomes in 8,160 heart transplant recipients in recent era. Ann Thorac Surg. 2007;84:1556–63.  https://doi.org/10.1016/j.athoracsur.2007.05.095.CrossRefPubMedGoogle Scholar
  15. 15.
    Chin C, Chen G, Sequeria F, Berry G, Siehr S, Bernstein D, et al. Clinical usefulness of a novel C1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients. J Hear Lung Transplant. 2011;30:158–63.  https://doi.org/10.1016/j.healun.2010.08.020.CrossRefGoogle Scholar
  16. 16.
    Loupy A, Lefaucheur C, Vernerey D, Prugger C, van Huyen J-PD, Mooney N, et al. Complement-binding anti-hla antibodies and kidney-allograft survival. N Engl J Med. 2013;369:1215–26.  https://doi.org/10.1056/NEJMoa1302506.CrossRefPubMedGoogle Scholar
  17. 17.
    Chih S, Chong AY, Mielniczuk LM, Bhatt DL, Beanlands RSB. Allograft vasculopathy the Achilles’ heel of heart transplantation. J Am Coll Cardiol. 2016;68:80–91.CrossRefGoogle Scholar
  18. 18.
    Cole RM, Kobashigawa JA. Desensitization strategies pre- and post-cardiac transplantation. Curr Treat Options Cardiovasc Med. 2016;18:8.CrossRefGoogle Scholar
  19. 19.
    Geft D, Kobashigawa J. Current concepts for sensitized patients before transplantation. Curr Opin Organ Transplant. 2017;22:236–41.CrossRefGoogle Scholar
  20. 20.
    Valantine H. Cardiac allograft vasculopathy after heart transplantation: risk factors and management. J Hear Lung Transpl. 2004;23:S187–93.  https://doi.org/10.1016/j.healun.2004.03.009.CrossRefGoogle Scholar
  21. 21.
    Chang DH, Kittleson MM, Kobashigawa JA. Immunosuppression following heart transplantation: prospects and challenges. Immunotherapy. 2014.Google Scholar
  22. 22.
    Andreassen AK, Andersson B, Gustafsson F, Eiskjær H, Gude E, Jansson K, et al. Everolimus initiation and early calcineurin inhibitor withdrawal in heart transplant recipients: a randomized trial. Am J Transplant. 2014;14:1828–38.  https://doi.org/10.1111/ajt.12809.CrossRefPubMedGoogle Scholar
  23. 23.
    Baraldo M, Gregoraci G, Livi U. Steroid-free and steroid withdrawal protocols in heart transplantation: the review of literature. Transpl Int. 2014;27:515–29.CrossRefGoogle Scholar
  24. 24.
    Rosenbaum DH, Adams BC, Mitchell JD, Jessen ME, Paul MC, Kaiser PA, et al. Effects of early steroid withdrawal after heart transplantation. Ann Thorac Surg. 2006;82:637–44.  https://doi.org/10.1016/j.athoracsur.2006.03.067.CrossRefPubMedGoogle Scholar
  25. 25.
    Baran DA, Zucker MJ, Arroyo LH, Camacho M, Goldschmidt ME, Nicholls SJ, et al. A prospective, randomized trial of single-drug versus dual-drug immunosuppression in heart transplantation: the tacrolimus in combination, tacrolimus alone compared (TICTAC) trial. Circ Hear Fail. 2011;4:129–37.  https://doi.org/10.1161/CIRCHEARTFAILURE.110.958520.CrossRefGoogle Scholar
  26. 26.
    Deckers JW, Hare JM, Baughman KL. Complications of transvenous right ventricular endomyocardial biopsy in adult patients with cardiomyopathy: a seven-year survey of 546 consecutive diagnostic procedures in a tertiary referral center. J Am Coll Cardiol. 1992;19:43–7.  https://doi.org/10.1016/0735-1097(92)90049-S.CrossRefPubMedGoogle Scholar
  27. 27.
    Marboe CC, Billingham M, Eisen H, Deng MC, Baron H, Mehra M, et al. Nodular endocardial infiltrates (Quilty lesions) cause significant variability in diagnosis of ISHLT grade 2 and 3A rejection in cardiac allograft recipients. J Heart Lung Transplant. 2005;24:S219–26.CrossRefGoogle Scholar
  28. 28.
    Crespo-Leiro MG, Stypmann J, Schulz U, Zuckermann A, Mohacsi P, Bara C, et al. Clinical usefulness of gene-expression profile to rule out acute rejection after heart transplantation: CARGO II. Eur Heart J. 2016;37:2591–601.  https://doi.org/10.1093/eurheartj/ehv682.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    •• Pham MX, Teuteberg JJ, Kfoury AG, Starling RC, Deng MC, Cappola TP, et al. Gene-expression profiling for rejection surveillance after cardiac transplantation. N Engl J Med. 2010;362:1890–900.  https://doi.org/10.1056/NEJMoa0912965. This randomized trial demonstrated the noninferiority of a surviellance strategy utilizing gene expression profiling, as compared with routine biopsies, was not associated with an increased risk of serious adverse outcomes. CrossRefGoogle Scholar
  30. 30.
    Kobashigawa J, Patel J, Azarbal B, Kittleson M, Chang D, Czer L, et al. Randomized pilot trial of gene expression profiling versus heart biopsy in the first year after heart transplant: early invasive monitoring attenuation through gene expression trial. Circ Heart Fail. 2015;8:557–64.  https://doi.org/10.1161/CIRCHEARTFAILURE.114.001658.CrossRefPubMedGoogle Scholar
  31. 31.
    Lo YMD, Tein MSC, Pang CCP, Yeung CK, Tong KL, Magnus Hjelm N. Presence of donor-specific DNA in plasma of kidney and liver-transplant recipients. Lancet. 1998;351:1329–30.  https://doi.org/10.1016/S0140-6736(05)79055-3.CrossRefPubMedGoogle Scholar
  32. 32.
    Beck J, Bierau S, Balzer S, Andag R, Kanzow P, Schmitz J, et al. Digital droplet PCR for rapid quantification of donor DNA in the circulation of transplant recipients as a potential universal biomarker of graft injury. Clin Chem. 2013;59:1732–41.  https://doi.org/10.1373/clinchem.2013.210328.CrossRefPubMedGoogle Scholar
  33. 33.
    De Vlaminck I, Valantine HA, Snyder TM, Strehl C, Cohen G, Luikart H, et al. Circulating cell-free DNA enables noninvasive diagnosis of heart transplant rejection. Sci Transl Med. 2014;6:241ra77.  https://doi.org/10.1126/scitranslmed.3007803.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Halloran PF, Reeve JP, Pereira AB, Hidalgo LG, Famulski KS. Antibody-mediated rejection, T cell-mediated rejection, and the injury-repair response: new insights from the Genome Canada studies of kidney transplant biopsies. Kidney Int. 2014;85:258–64.  https://doi.org/10.1038/ki.2013.300.CrossRefPubMedGoogle Scholar
  35. 35.
    Mengel M, Sis B, Kim D, Chang J, Famulski KS, Hidalgo LG, et al. The molecular phenotype of heart transplant biopsies: relationship to histopathological and clinical variables. Am J Transplant. 2010;10:2105–15.  https://doi.org/10.1111/j.1600-6143.2010.03182.x.CrossRefPubMedGoogle Scholar
  36. 36.
    Halloran PF, Potena L, Van Huyen JPD, Bruneval P, Leone O, Kim DH, et al. Building a tissue-based molecular diagnostic system in heart transplant rejection: the heart molecular microscope diagnostic (MMDx) system. J Heart Lung Transplant. 2017;36:1192–200.  https://doi.org/10.1016/j.healun.2017.05.029.CrossRefPubMedGoogle Scholar
  37. 37.
    Tobis JM. Cardiac transplant vasculopathy. Catheter Cardiovasc Interv. 2017;90:56–7.CrossRefGoogle Scholar
  38. 38.
    Lund LH, Edwards LB, Kucheryavaya AY, Dipchand AI, Benden C, Christie JD, et al. The registry of the International Society for Heart and Lung Transplantation: thirtieth official adult heart transplant report - 2013; focus theme: Age. J Hear Lung Transplant. 2013;32:951–64.  https://doi.org/10.1016/j.healun.2013.08.006.CrossRefGoogle Scholar
  39. 39.
    Kobashigawa JA, Tobis JM, Starling RC, Tuzcu EM, Smith AL, Valantine HA, et al. Multicenter intravascular ultrasound validation study among heart transplant recipients: outcomes after five years. J Am Coll Cardiol. 2005;45:1532–7.CrossRefGoogle Scholar
  40. 40.
    Wever-Pinzon O, Romero J, Kelesidis I, Wever-Pinzon J, Manrique C, Budge D, et al. Coronary computed tomography angiography for the detection of cardiac allograft vasculopathy: a meta-analysis of prospective trials. J Am Coll Cardiol. 2014;63:2005–6.  https://doi.org/10.1016/j.jacc.2014.01.071.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Kevin S. Shah
    • 1
  • Michelle M. Kittleson
    • 1
  • Jon A. Kobashigawa
    • 1
  1. 1.Cedars-Sinai Smidt Heart InstituteLos AngelesUSA

Personalised recommendations